Hepatocellular carcinoma in Peru: A molecular description of an unconventional clinical presentation.
Rev Gastroenterol Mex (Engl Ed)
; 2023 May 08.
Article
em En
| MEDLINE
| ID: mdl-37164797
ABSTRACT
INTRODUCTION AND AIM:
Hepatocellular carcinoma (HCC) is the third most frequent cancer of digestive tract tumors in Peru, with a high mortality rate of 17.7 per 100,000 inhabitants. A significant number of HCC cases in Peru do not follow the classic clinical epidemiology of the disease described in other parts of the world. Those patients present with a distinct transcriptome profile and a singular tumor process, suggesting a particular type of hepatocarcinogenesis in a portion of the Peruvian population. Our aim was to understand the clinical and biologic involvement of the epigenetic profile (methylation) and gene expression (transcriptome) of HCC in Peruvian patients.METHODS:
HCC and liver transcriptome and DNA methylation profiles were evaluated in 74 Peruvian patients.RESULTS:
When grouped by age, there was greater DNA methylation in younger patients with HCC but no differences with respect to the transcriptomic profile. A high prevalence of the hepatitis B virus (HBV) (>90%) was also observed in the younger patients with HCC. Enrichment analyses in both molecular profiles pinpointed PRC2 as an important molecular effector of that liver tumor process in Peruvian patients.CONCLUSION:
HCC in Peruvian patients has a unique molecular profile, associated with the presence of HBV, as well as overall DNA hypermethylation related to undifferentiated liver cells or cellular reprogramming.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Risk_factors_studies
País/Região como assunto:
America do sul
/
Peru
Idioma:
En
Revista:
Rev Gastroenterol Mex (Engl Ed)
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Peru